The Okayama Lung Cancer Study Group Experience: A Comparison of the Incidence and Pattern of Interstitial Lung Disease during Erlotinib and Gefitinib Treatment in Japanese Patients with Non-Small Cell Lung Cancer

Katsuki Hotta

The Okayama Lung Cancer Study Group Experience: A Comparison of the Incidence and Pattern of Interstitial Lung Disease during Erlotinib and Gefitinib Treatment in Japanese Patients with Non-Small Cell Lung Cancer

Katsuki Hotta^*: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

^*Corresponding Author : Katsuki Hotta, Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan, Email: kathotta@md.okayama-u.ac.jp

Received Date: May 29, 2023 / Published Date: Jun 29, 2023

View PDF Download PDF

Citation: Hotta K (2023) The Okayama Lung Cancer Study Group Experience:A Comparison of the Incidence and Pattern of Interstitial Lung Disease duringErlotinib and Gefitinib Treatment in Japanese Patients with Non-Small Cell LungCancer. Int J Inflam Cancer Integr Ther, 10: 227.

Copyright: © 2023 Hotta K. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

91桃色

International Journal of Inflammation, Cancer and Integrative Therapy
Open 91桃色